The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies.
The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies.
复制标题
DOI：
10.1186/1472-6823-14-9
复制
发表时间：
2014-02-01
影响因子：
2.7
通讯作者：
Wolffenbuttel BH
中科院分区：
文献类型：
--
作者：
van Vliet-Ostaptchouk JV;Nuotio ML;Slagter SN;Doiron D;Fischer K;Foco L;Gaye A;Gögele M;Heier M;Hiekkalinna T;Joensuu A;Newby C;Pang C;Partinen E;Reischl E;Schwienbacher C;Tammesoo ML;Swertz MA;Burton P;Ferretti V;Fortier I;Giepmans L;Harris JR;Hillege HL;Holmen J;Jula A;Kootstra-Ros JE;Kvaløy K;Holmen TL;Männistö S;Metspalu A;Midthjell K;Murtagh MJ;Peters A;Pramstaller PP;Saaristo T;Salomaa V;Stolk RP;Uusitupa M;van der Harst P;van der Klauw MM;Waldenberger M;Perola M;Wolffenbuttel BH
并不是所有的肥胖受试者都有不良的代谢特征，使他们易患2型糖尿病或心血管疾病。BioSHaRE-EU健康肥胖项目旨在利用几项大规模队列研究的风险因素和表型数据，深入了解（健康）肥胖的后果。本研究的目的是描述10项参与研究中肥胖、代谢综合征（MetS）和代谢健康性肥胖（MHO）的患病率。将7个国家的10个不同群组合并，使用的数据转换成统一格式。所有参与者都是欧洲血统，年龄在18-80岁之间。他们参加了人体测量和血压测量的临床检查。抽取血液样本进行血脂和葡萄糖分析。根据2001年NCEP ATP III标准以及一组适用的不太严格的标准，评估肥胖患者（BMI ≥ 30 kg/m2）中MetS的存在情况。MHO被定义为肥胖，没有MetS组分，并且先前没有心血管疾病的诊断。163，517人的数据可用; 17%为肥胖（11，465名男性和16，612名女性）。肥胖的患病率从意大利CHRIS队列的11.6%到德国KORA队列的26.3%不等。患有代谢综合征的肥胖受试者的年龄标准化百分比在女性中的范围从CHRIS的24%到芬兰健康2000队列的65%，在男性中从CHRIS的43%到芬兰DILGOM队列的78%，血压升高是导致代谢综合征患病率的最常见因素。女性MHO的年龄标准化患病率从Health 2000的7%到NCDS的28%不等，男性从DILGOM的2%到CHRIS的19%不等。MHO在女性中比男性更普遍，并且随着年龄的增长而下降。通过严格的协调过程，BioSHaRE-EU联盟能够比较十项队列研究中定义代谢健康肥胖表型的关键特征。在研究的不同欧洲人群中，健康肥胖的患病率存在相当大的差异，即使使用统一的标准对这种表型进行分类。
Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity (MHO) in ten participating studies. Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All participants were of European origin, with age 18–80 years. They had participated in a clinical examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001 NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS components, and no previous diagnosis of cardiovascular disease. Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in women than in men, and decreased with age in both sexes. Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence of healthy obesity across the different European populations studied, even when unified criteria were used to classify this phenotype.
登录
查看更多内容
DOI：
10.1161/atvbaha.107.151092
发表时间：
2008-04-01
影响因子：
8.7
作者：
Grundy, Scott M.
通讯作者：
Grundy, Scott M.
影响因子：
2.3
作者：
Doiron D;Burton P;Marcon Y;Gaye A;Wolffenbuttel BHR;Perola M;Stolk RP;Foco L;Minelli C;Waldenberger M;Holle R;Kvaløy K;Hillege HL;Tassé AM;Ferretti V;Fortier I
通讯作者：
Fortier I
DOI：
10.1016/s0140-6736(10)62037-5
发表时间：
2011-02-12
期刊：
Lancet (London, England)
影响因子：
--
作者：
Finucane MM;Stevens GA;Cowan MJ;Danaei G;Lin JK;Paciorek CJ;Singh GM;Gutierrez HR;Lu Y;Bahalim AN;Farzadfar F;Riley LM;Ezzati M;Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index)
通讯作者：
Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index)
影响因子：
4.9
作者：
Kelly, T.;Yang, W.;He, J.
通讯作者：
He, J.
影响因子：
8.2
作者：
Karelis, A. D.;Messier, V.;Rabasa-Lhoret, R.
通讯作者：
Rabasa-Lhoret, R.